Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation

<table>(a) Sensitivity analysis of the AI parameter when the cytotoxic chemotherapy parameter is fixed at <svg height="14.6" id="M124" style="vertical-align:-3.13504pt" version="1.1" viewbox="0 0 61.549999 14.6" width="61.549999" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,14.6)">
<g transform="translate(72,-60.32)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑇</tspan>
</text>
<text transform="matrix(1,0,0,-1,-65.07,60.37)">
<tspan style="font-size: 8.75px; " x="0" y="0">2</tspan>
</text>
<text transform="matrix(1,0,0,-1,-56.73,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="12.040389" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="18.291889" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="21.417639" y="0">3</tspan>
<tspan style="font-size: 12.50px; " x="27.66914" y="0">4</tspan>
</text>
</g>
</g>
</svg>. (b) Sensitivity analysis of the cytotoxicity parameter when the AI parameter is fixed at <svg height="14.6" id="M125" style="vertical-align:-3.13504pt" version="1.1" viewbox="0 0 57.650002 14.6" width="57.650002" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,14.6)">
<g transform="translate(72,-60.32)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑇</tspan>
</text>
<text transform="matrix(1,0,0,-1,-65.07,60.37)">
<tspan style="font-size: 8.75px; " x="0" y="0">1</tspan>
</text>
<text transform="matrix(1,0,0,-1,-56.73,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="12.040389" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="18.291889" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="24.543388" y="0">0</tspan>
</text>
</g>
</g>
</svg>.</table>

Computational and Mathematical Methods in Medicine

fig5

Figure 5

Figure 5: Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation 